Evidence strength for the context described on this page.
PEPTIDE ATLAS / MUSCLE & RECOVERY / MECASERMIN
EvidenceHigh for approved indicationi
RegulatoryFDA-approvedi
Mecasermin

Prescription IGF-1 for severe primary IGF-1 deficiency—not a bodybuilding peptide.
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read the evidence limits
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
The five facts to know first.
Status is product-, formulation- and indication-specific.
Public education does not establish a personal treatment plan.
Plus 0 research searches. A search link is not a cited study or proof of a claim.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗Where present, the date above records an editorial content review, not medical approval or a live check of every claim. Follow the official product label and regulator links for current status. This page does not establish availability through Modern Bio.
How we describe evidence →OVERVIEW
What Mecasermin is.
Recombinant human insulin-like growth factor-1 approved for growth failure from age 2 in patients with severe primary IGF-1 deficiency, or growth hormone gene deletion with neutralizing antibodies to growth hormone.
Replaces deficient IGF-1 signaling to support linear growth and metabolic effects.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- Improves growth in the labeled pediatric deficiency population
- Safe muscle gain in healthy adults
- Anti-aging
- Athletic performance enhancement
- Use as an IGF-1 LR3 substitute
Evidence grade: High for approved indication. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
CLINICAL CONTEXT
The decision is individual.
Approval applies to a specific product and indication. A licensed clinician must evaluate whether the exact treatment fits your history, current medications and goals.
Identify the outcome, formulation and population actually studied.
Review benefits, uncertainty, contraindications and better-studied alternatives.
A treatment decision needs a responsible clinician, monitoring and a review date.
This public guide does not provide a dosing, injection or self-treatment protocol. Bring the source links and the exact product into a licensed clinical consultation.
MONITORING
What should be tracked.
- Glucose and hypoglycemia, including the label’s food precautions
- Growth response
- Intracranial hypertension symptoms
- New limp or hip/knee pain needs prompt evaluation
- Tonsillar/adenoidal growth, scoliosis and neoplasia surveillance
SAFETY
Risks, red flags and reasons to avoid it.
- Severe hypoglycemia, including seizures
- Intracranial hypertension
- Tonsillar hypertrophy and sleep-disordered breathing
- Malignant neoplasia warning
- Closed growth plates
- Active or suspected malignancy
- Unsupervised adult performance use
- Confusing mecasermin with unapproved IGF-1 LR3
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
SOURCES & RESEARCH LINKS
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. Vendor and community dosing protocols are excluded from this public source list. These are supporting reading links, not a completed claim-by-claim citation map. Search links can lead to changing results; their presence does not establish that a particular study supports this profile.
PRODUCTS & TREATMENT ACCESS
Use a verified prescription pathway.
Specialty prescription FDA-approved product for a narrow pediatric indication.
The existence of approved IGF-1 therapy does not validate gray-market IGF-1 analogs or bodybuilding protocols.
Learn now. Verify care separately.
This guide is not a booking or prescribing service. Clinical appointments and prescription decisions are handled separately from this educational Atlas.
Review care readiness and standards →NEXT STEP
Return to muscle & recovery peptides.
Explore the category →YOUR NEXT STEP
Ready for a clinician-led plan?
Clinical review determines the appropriate next step. No treatment is guaranteed.
THE CARE PATH
We order your labs
A licensed clinician reviews results and recommends a plan
Rx sent directly to you when appropriate
Care depends on eligibility and clinical judgment. No prescription is guaranteed. This pathway is not a recommendation for the treatment or test discussed in this guide.
Start your lab reviewExplore free educational tools